Shanrong Biotechnology(SRBT)
$0.050.00 (0.00%)
SRBT
Shanrong Biotechnology financials statements
$0.05
At close:0.00 (0.00%)
Shanrong Biotechnology (SRBT) Ratios
5 Followers
Shanrong Biotechnology Ratios
SRBT's free cash flow for Q3 2023 was $-8.75K. For the 2023 fiscal year, SRBT's free cash flow was increased by $0.00 and operating cash flow was $-8.75K. See a summary of the company’s cash flow.
| Ratios | Dec 22 | Dec 17 |
|---|---|---|
| Liquidity Ratios | ||
| Current Ratio | 10.07 | 0.39 |
| Quick Ratio | 10.07 | 0.39 |
| Cash Ratio | 10.07 | 0.39 |
| Solvency Ratio | 1.54 | 0.32 |
| Operating Cash Flow Ratio | -42.49 | -0.50 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 |
| Net Current Asset Value | $ -78.98K | $ -39.21K |
| Leverage Ratios | ||
| Debt-to-Assets Ratio | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.24 | -0.63 |
| Debt Service Coverage Ratio | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.23 | 0.78 |
| Profitability Margins | ||
| Gross Profit Margin | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% |
| EBT Per EBIT | 99.99% | 100.01% |
| Return on Assets (ROA) | -431.70% | -128.16% |
| Return on Equity (ROE) | 102.60% | 80.98% |
| Return on Capital Employed (ROCE) | -479.31% | 80.97% |
| Return on Invested Capital (ROIC) | -479.31% | 80.97% |
| Return on Tangible Assets | -431.70% | -128.16% |
| Earnings Yield | -21.72% | -6.06% |
| Efficiency Ratios | ||
| Receivables Turnover | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 |
| Cash Flow Ratios | ||
| Operating Cash Flow Per Share | -0.16 | -0.07 |
| Free Cash Flow Per Share | -0.16 | -0.07 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 |
| Free Cash Flow Yield | -21.22% | -6.06% |
| Valuation Ratios | ||
| Price-to-Earnings (P/E) Ratio | -4.60 | -16.49 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -4.72 | -13.35 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.71 | -16.49 |
| Price-to-Operating Cash Flow Ratio | -4.71 | -16.49 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -1.36 |
| Enterprise Value Multiple | -4.37 | -15.71 |
| Enterprise Value | 345.34K | 498.86K |
| EV to EBITDA | -4.37 | -15.71 |
| EV to Sales | 0.00 | 0.00 |
| EV to Free Cash Flow | -4.48 | -15.71 |
| EV to Operating Cash Flow | -4.48 | -15.71 |
| Tangible Book Value Per Share | -0.16 | -0.08 |
| Shareholders’ Equity Per Share | -0.16 | -0.08 |
| Tax and Other Ratios | ||
| Effective Tax Rate | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 |
| Net Income Per Share | -0.16 | -0.07 |
| Tax Burden | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 |
| Income Quality | 0.98 | 1.00 |
Currency in USD
